Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry.

ABSTRACT:

Objective

To examine in detail the outcomes of biologic DMARD (bDMARD) discontinuation while in remission occurring in daily clinical practice settings. We examined a multicentre longitudinal registry of RA patients.

Methods

We utilized data from the NinJa multicenter registry in Japan. Patients who used bDMARDs and had one or more successive visits in remission (defined by the clinical disease activity index (CDAI) ≤2.8) before discontinuation were included. The outcome of failing bDMARD-free disease control was defined as a composite of the following: re-use of bDMARDs, intensification of non-biologic DMARDs or of oral glucocorticoids, or loss of CDAI remission.

Results

Among 1037 patients who initially achieved remission on bDMARDs, 46 patients discontinued bDMARDs

SUBMITTER: Yoshida K 

PROVIDER: S-EPMC4751227 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature